To inspire is to stimulate... motivate... activate.

For the past 22 years, the Alzheimer's Drug Discovery Foundation (ADDF) has been providing a backbone for scientific discovery and drug development in the Alzheimer's research arena, serving as a significant driver of meaningful innovation and change.

We have partnered with top researchers to aid in the incubation of novel ideas in the quest to find answers for a disease that for decades has confounded the medical and science communities. We are proud of the key role we have played in broadening the focus of discovery towards the biology of aging—shifting the research landscape.

Key advances in 2020 indicate that we are truly hitting our stride. Many initiatives with the ADDF’s footprint are paying off in breakthrough firsts, including the first diagnostic blood test to come to clinic for Alzheimer’s disease. More than ever, we see continued great promise and potential ahead, and it is our mission to capture it.
Dear Friends,

A global pandemic—the first of its kind in over 100 years—made 2020 a year unlike any other. Despite the challenges posed by the COVID-19 pandemic, 2020 was a great year for Alzheimer’s research and the Alzheimer’s Drug Discovery Foundation. Our leadership, dedication and investment were reflected in so many of the advances we saw last year.

The ADDF has been inspiring change for more than 20 years—encouraging new approaches to Alzheimer’s research. Our early, bold vision is now mainstream with researchers across the globe looking at novel and repurposed drugs that target the many age-related changes that contribute to Alzheimer’s.

You will read in this report how ADDF support helped bring the first-ever blood test to market for early detection of Alzheimer’s disease with another blood test on the horizon. Our Diagnostics Accelerator program continues to lead the way in the development of blood tests and other biomarkers by investing in innovative ideas and bringing the research community together to share and grow its knowledge.

You will read about the many research initiatives we nurtured that have advanced into phase 2 clinical trials. Several reported positive results and more are expected to report soon. Our venture philanthropy model also proves itself time and again with many of our early investments helping to attract larger funding streams from government agencies like the National Institute on Aging, private investors, and large pharmaceutical companies.

This report features our ongoing efforts to uncover and share growing evidence about the benefit of prevention and brain health. Our Cognitive Vitality program provides credible, science-based strategies to help prevent Alzheimer’s disease and related dementias.

We are on the cusp of exciting progress. The ADDF will continue its trademark dedication as we close in on treatments and cures for Alzheimer’s and related diseases.

We are forever grateful to you for adopting our goals as your own. With your ongoing support, we come closer every day to changing the course of this devastating disease.

The ADDF will not stop until we satisfy our mission. You have our promise.

Leonard A. Lauder
Co-Chairman and Co-Founder

Ronald S. Lauder
Co-Chairman and Co-Founder
Dear Friends,

I have been proud to lead the scientific exploratory efforts at the Alzheimer’s Drug Discovery Foundation every single day of the past 22 years. But perhaps never more so than now. The ADDF has played a major role in driving innovative ideas that have advanced—and will continue to advance—the Alzheimer’s research field.

The ADDF was instrumental in shifting the dial from a single-minded focus on misfolded amyloid and tau proteins towards an exploration of all the biological aspects of the aging process that contribute to the development and progression of Alzheimer’s. We have inspired a sea change in approach that has altered the course of Alzheimer’s drug discovery and development, with tremendous progress in just the past five years.

We have evolved from a boutique supporter of pre-clinical research to a dominant force in clinical development research. In 2020, we rode this trajectory into a “modern era” of Alzheimer’s research. Our robust and diverse pipeline of drugs in development reflects our translation of the biology of aging into cutting-edge therapeutics for Alzheimer’s disease.

This report details our accomplishments as we worked with leading scientists to explore novel targets, repurposed drugs, and supported innovative prevention strategies. We also helped drive advances in diagnostic biomarkers—including the breakthrough launch by C2N Diagnostics of the first-ever commercially available blood test for Alzheimer’s disease. We continue to contribute to the development of even more novel diagnostics through our Diagnostics Accelerator.

I am more excited and hopeful about Alzheimer’s research with every passing year. Phase 2 studies of many potential treatments are reporting their results. We continue to collaborate with leading scientists and marquee-name investors who will take us to the next level in our quest, and we have a new diagnostic test on the market with more to follow. We are closer than ever to capturing the promise of effective drugs to treat and prevent Alzheimer’s disease.

With gratitude for your continued support,

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
At the ADDF, we know there is more than one solution to the Alzheimer’s puzzle. Our long-term goal is to uncover a variety of treatments that can ultimately be individualized to suit each patient’s needs. As such, our drug development philosophy calls for using a broad range of approaches to improve the likelihood for success, envisioning a future of combination therapy.

Our record-high 2020 investment of over $30 million to support more than 100 new and continuing active research projects was in sync with our mission to develop drugs that work on various pathways—addressing the full range of possible causes of Alzheimer’s disease. For years, our contributions have inspired the scientific community to consider approaches beyond amyloid, encouraging exploration of additional targets associated with the biology of aging. We have been instrumental in leading the way in investigations of other misfolded proteins (such as tau), inflammation, vascular problems, genetic mutations, metabolic brain dysfunction, and other age-related changes.

“When years of discovery, we are now hitting our stride across multiple areas of the Alzheimer’s disease landscape, with the promise of more to come.”

Mark Roithmayr
Chief Executive Officer

Global pandemic notwithstanding, we sustained our influencer role and remained a leading catalyst for driving innovation in Alzheimer’s drug discovery, including these highlights:

- An ADDF-funded blood test, first to come to the clinic, revolutionized the ability to detect Alzheimer’s
- An ADDF-supported brain imaging breakthrough played a key role in a pivotal drug trial
- Numerous ADDF-backed drug trials moved forward with repurposed drugs front and center
INSPIRING CHANGE
OUR VENTURE PHILANTHROPY MODEL PROMISES ONGOING INNOVATION

At the ADDF, our distinctive approach to funding allows us to invest money and resources in bold ideas that can speed the development of drugs, biomarkers, and diagnostic tools for Alzheimer’s. We identify promising concepts that may have been deemed too risky to attract investment capital. Our early involvement frequently serves as a bridge, allowing studies to advance to the point where other investors—including the pharmaceutical industry and government agencies—are willing to jump in with support.

An example of this funding progression occurred in 2020, as Cognition Therapeutics, which the ADDF began supporting more than 10 years ago, was awarded over $75 million from the National Institute on Aging (NIA) for its phase 2 clinical trial program of a neuro-protective drug with disease-slowing and possible disease-preventing properties.

Employing a venture philanthropy approach as our business model for over 20 years, we make mission-related investments in research. Our model combines deep, disease-focused expertise with funding for research programs from academia and biotech companies worldwide. When our programs succeed, we re-invest our mission-related returns in further research.

Since its inception, the ADDF has generated returns of $22 million, with more than $4 million in 2020 alone.

A key feature of our venture philanthropy approach is our high level of engagement and long-term commitment to our partners. 2020 highlights include:

- **Tetra Therapeutics** engaged in a $500 million deal to merge with Shionogi Inc., a research-driven pharmaceutical company, to develop Tetra’s portfolio of products for the treatment of brain disorders associated with cognitive deficits.

- **Vanderbilt University** entered a $515 million licensing agreement with Acadia Pharmaceuticals to advance its cognitive enhancing, potentially neuroprotective drug into phase 2 clinical trials.

"Our funding model is about advancing the research so we can get effective treatments into the hands of patients and their families."

**Mark Roithmayr**
*Chief Executive Officer*
AN ADDF-FUNDED BLOOD TEST FIRST TO CLINIC REVOLUTIONIZED THE ABILITY TO DETECT ALZHEIMER’S

Meaningful progress was made in the long-standing challenge to develop less costly, more accessible methodologies for spotting signs of Alzheimer’s and diagnosing disease. Our $2.8 million decade-long investment in C2N Diagnostics’ research paid off with their launch of PrecivityAD™ in October 2020. This breakthrough test uses just a small blood sample to identify whether amyloid plaques—a hallmark of Alzheimer’s—are present in a patient’s brain, warranting more extensive memory and cognitive evaluation. The ability to easily and non-invasively detect Alzheimer’s in vulnerable patients will improve the quality of clinical trials and enhance patient care for decades to come.

“Our funding helped bring the first FDA-approved diagnostic PET brain scan to market and now has helped bring the first Alzheimer’s blood test to market.”

Howard Fillit, MD
Founding Executive Director and Chief Science Officer

OUR FOOTPRINT IN BIOMARKERS

THE ADDF’S COMMITMENT TO ZERO IN ON ALZHEIMER’S TREATMENTS IS ACCOMPANIED BY OUR SIMULTANEOUS EFFORTS TO EXPAND THE WAYS TO DETECT THE DISEASE.

Biomarkers play a critical role in research, diagnosis, and treatment decisions, as there are still relatively few ways to identify Alzheimer’s presence. While the Amyvid™ PET scan revolutionized diagnostics and clinical trial patient enrollment, high costs have limited its use. Other tests such as spinal taps are invasive and costly as well. With more therapies focused on novel targets, such as inflammation or vascular issues, we will
AN ADDF-SUPPORTED BRAIN IMAGING BREAKTHROUGH PLAYED A KEY ROLE IN PIVOTAL DRUG TRIAL

For years we could only test drugs in patients who were presumed to have Alzheimer’s. Approximately 30% of patients participating in Alzheimer’s trials just a decade ago did not even have the disease. This means the data in those earlier clinical trials were flawed and inadequate to prove a drug’s effectiveness. That changed dramatically thanks to early backing by the ADDF in the development of Amyvid™, a PET imaging test that can detect amyloid plaques in the brain. In 2020, this cutting-edge diagnostic tool was used in Biogen’s phase 3 clinical trials of aducanumab (Aduhelm), which targets amyloid. Considered landmark trials, they were among the first to use a validated biomarker test to ensure the right patients were enrolled and to measure the drug’s impact in the brain.

Today’s trials are more rigorous than ever, having been built on years of research learnings, plus growing availability of Alzheimer’s biomarkers and better use of them in clinical trials.

need a myriad of ways to detect the irregularities that might spell Alzheimer’s risk or presence. Biomarkers are important for a diverse armament of drugs that can be combined for personalized medicine—the future of managing Alzheimer’s.

Our Diagnostics Accelerator (DxA) initiative has united influential philanthropists and researchers in the ongoing quest to fast-track discovery of reliable, cost-effective, and user-friendly Alzheimer’s biomarkers. With funding commitments totaling $50 million since its 2018 inception, the DxA has supported dozens of world-class researchers in their investigations of novel diagnostic technologies to simplify Alzheimer’s detection, including blood/genetic tests, eye scans, and digital tools—all of which are critical to advancing research.

Our investments made through the DxA promise more and better biomarkers will come to market within the next five to 10 years.

At the ADDF, we envision a time when a single blood sample, simple eye scan, or even a smartphone app will be able to identify several signs of Alzheimer’s, allowing for individualized precision medicine treatments matched to a patient’s unique pathology.
NUMEROUS ADDF-BACKED DRUG TRIALS MOVED FORWARD WITH REPURPOSED DRUGS FRONT AND CENTER

Our diverse portfolio—35 clinical trials strong in 2020—is one of the largest worldwide. As always, our 360-degree approach focused on supporting innovative new drugs and targets. We continued to support studies that aim to repurpose drugs already approved for other indications for use in Alzheimer’s disease, as prior FDA approvals mean shorter research timelines and reduced costs. In 2020, repurposed agents accounted for nearly half of our portfolio. Studies of the following agents were among those that provided successful phase 2 result read-outs, indicating Alzheimer’s disease potential and readiness for phase 3 trials.

Repurposed agents accounted for 49% of our portfolio

49%
We are deeply appreciative to the ADDF not just for their program development assistance and investment in our work, but for their commitment to novel scientific approaches to Alzheimer’s research.

Ana Pereira, MD

**RILUZOLE, APPROVED FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)**

Ana Pereira, MD, of New York City’s Icahn School of Medicine at Mount Sinai Hospital demonstrated that this drug modulates levels of glutamate, a brain neurotransmitter, resulting in significantly less decline in cerebral metabolism—strongly correlated with cognitive performance—in patients with mild Alzheimer’s.

“We are deeply appreciative to the ADDF not just for their program development assistance and investment in our work, but for their commitment to novel scientific approaches to Alzheimer’s research.”

Ana Pereira, MD

**LIRAGLUTIDE, APPROVED FOR DIABETES**

Paul Edison, MD, PhD, of Imperial College London presented data indicating that this agent, an analog of the hormone GLP-1, helps normalize the brain’s use of glucose energy and its insulin signaling ability, which can be desensitized in Alzheimer’s patients. Benefits include potential reduction of brain atrophy and grey matter loss and significant improvement in executive function and temporal lobe volume.

“Our results from this 12-month phase 2b trial show there was a significant improvement in executive function, temporal lobe volume, and total grey matter in the liraglutide-treated patients compared with placebo.”

Paul Edison, MD, PhD

**ROTIGOTINE, APPROVED FOR PARKINSON’S DISEASE**

Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome showed that this drug works on the brain neurotransmitter dopamine to improve cognitive function in patients with mild-to-moderate Alzheimer’s.

“This study could open novel therapeutic options focused on dopaminergic transmission to treat patients early—when the cognitive functions related to frontal lobe activity and daily life abilities are only mildly impaired—to delay the onset of full-blown Alzheimer’s disease dementia.”

Giacomo Koch, MD, PhD
SHEPHERDING A ROBUST CLINICAL PIPELINE TOWARDS A PROMISING FUTURE

Our commitment to phase 2 studies persisted in 2020, representing 74% of the clinical trials we supported. As more agents approach phase 3, we eagerly anticipate the promise of approvals and patient access.
ACTIVE CLINICAL TRIALS BY PHASE

- Phase 0: 6%
- Phase 1: 17%
- Phase 2: 74%
- Phase 3: 3%

35 ACTIVE CLINICAL TRIALS
74% IN PHASE 2
Wile the ADDF has long been a leading force in exploring ways to treat existing cases of Alzheimer’s disease, we are simultaneously investigating intriguing ways to stay one step ahead of this formidable disease and stop it before it can take root. Delaying the onset of Alzheimer’s by five years may result in up to a 41% lower prevalence of the disease. In 2020, one half of the clinical trials in our portfolio were aimed at either preventing dementia or thwarting the advancement of early mild cognitive impairment into full-blown Alzheimer’s dementia.

INSPIRING SMARTER BRAIN HEALTH CHOICES TO AVERT DISEASE
As public interest in the relationship between brain health, Alzheimer’s, and the risks and benefits of various preventive measures has heightened, we responded by stepping up our focus on providing lifestyle and Alzheimer’s prevention information for patients, their families, and the medical community.

“The 2020 Lancet Commission gives us concrete steps we can take to reduce dementia risk or delay its onset.”

Yuko Hara, PhD
Director of Aging and Alzheimer’s Prevention
A New Resource for Researchers and Clinicians
Launched in January 2020, Cognitive Vitality Reports is a series of over 200 downloadable assessments from ADDF neuroscientists evaluating available evidence on the risks and benefits of various strategies to promote brain health and prevent not only dementia, but also other age-related brain concerns (e.g., cardiovascular diseases, cancers, diabetes). The reports include evaluations of FDA-approved drugs, drugs in development, herbal supplements and vitamins, foods and drinks, and other non-pharmacologic interventions. These reports allow healthcare professionals to make better-informed decisions about the safety and efficacy of available cognitive health interventions.

Credible, Science-Based Strategies
Our Cognitive Vitality website continues to offer a range of credible, science-based strategies to help people make smarter lifestyle decisions to promote brain health and potentially ward off disease. In 2020, our content also addressed pandemic-related concerns, adding timely blogs covering topics such as “Infection and Cognitive Decline” and “Loneliness During COVID-19.” Among the significant research we highlighted for patient and practitioner consideration was the latest Lancet Commission report, proposing that targeting 12 risk factors throughout life may delay or prevent up to 40% of dementia cases.

“Evaluating scientific evidence can be challenging, even for experts. Cognitive Vitality provides simple tools and resources for patients, physicians, and scientists to better understand the latest science-based findings about cognitive health.”

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
THE PROMISE OF RECORD-SETTING SUPPORT

Reimagining Efforts to Tell Our Story

Not even a global pandemic could quell the momentum of the ADDF’s ongoing efforts to inspire support for our cause. Without missing a beat, the ADDF community—a team of dedicated donors, volunteers, event chairs, researchers, and staff—came together to create and present novel ways to keep all engaged and informed.

Soon after our Third Annual Hope on the Horizon Luncheon was held in Palm Beach in March, the decision was made to transition all remaining 2020 symposia, luncheons, and fundraising events to a virtual format.

We continued to honor scientific excellence, celebrating the achievements of women scientists as we awarded the Melvin R. Goodes Prize for innovative research to Jerri M. Rook, PhD, of Vanderbilt University, and highlighted the research of Roberta Diaz Brinton, PhD, Director of the University of Arizona’s Center for Innovation in Brain Science, at our Tenth Annual Great Ladies Event.

And we were gratified that big name entertainment and sports luminaries, including Co-Founders of Hilarity for Charity, actor and entrepreneur Seth Rogen and screenwriter and director Lauren Miller Rogen, actress Marcia Gay Harden, country music artist Jay Allen, and Washington Capitals team member and Stanley Cup winner T.J. Oshie shared the powerful stories of how Alzheimer’s has touched their families at our Third Annual Memories Matter and Tenth Annual Great Ladies events. As in the past, we were privileged that marquee-name journalists, including Andrea Mitchell and ADDF Board of Governors member Paula Zahn, joined forces with us in hosting roles.

“Memories fuel so much of our greatest work, our proudest accomplishments, and thanks to this community, they help move the world toward better treatment and ultimately a cure for Alzheimer’s.”

Paula Zahn
Host of the Third Annual Memories Matter Event

We consistently brought our message directly into homes within our community, building even deeper connections and resulting in an unexpected dividend: incredible generosity from supporters, totaling over $4 million in contributions to help further Alzheimer’s research.
In 2020, the ADDF watched our base of loyal supporters expand to include a younger generation of professionals in their 20s and 30s who are investing their time and money in the promise of a world without Alzheimer’s.

Co-founded by J.P. Morgan private banker Gina Holzheimer and Josh Lauder—grandson of the ADDF’s Co-Founder Leonard A. Lauder—the Young Professionals Committee (YPC) hit the ground running in September 2019 and grew throughout 2020 to over 65 members, most with a family connection to the disease. As the group expanded, executive boards were created to help structure and drive fundraising efforts, which brought in over $100,000 via creative events such as a week of fitness classes promoting the healthy lifestyle associated with a reduced risk of Alzheimer’s. In July, YPC members were integrated into the ADDF’s Third Annual Memories Matter event, where they shared their own moving stories of loved ones affected by the disease.

“I started off wanting to be connected because it was a disease my grandfather had...Knowing I’m doing everything I can now to try to find a drug to prevent or slow down Alzheimer’s disease is really rewarding.”

Gina Holzheimer
Co-Founder, ADDF Young Professionals Committee
CAPTURING THE PROMISE OF OUR 2020 HONOREES

Research Associate Professor at Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, Jerri Rook, PhD, recipient of the Melvin R. Goodes Prize for innovative research at the Eleventh Annual Fall Luncheon and Symposium.

Photographer, humanitarian, and philanthropist Judy Glickman Lauder, honoree at the Third Annual Hope on the Horizon Palm Beach Luncheon. Top row from left to right: Mark Roithmayr, Heidi McWilliams, Bonnie Lautenberg, Howard Fillit. Bottom row from left to right: Leonard A. Lauder, Judy Glickman Lauder, Nancy Goodes.
Philanthropist, former Chairman of Buckingham Capital Management, and ADDF Board of Governors member Larry Leeds, recipient of the Charles Evans Award for leadership and advocacy in support of the prevention, treatment, and cure of Alzheimer’s disease at the Eleventh Annual Fall Luncheon and Symposium.

Event founders and ADDF board members, Stephanie Ginsberg and Wendy Wilshin, at the Third Annual Memories Matter Event.

Founding Executive Chair of the Great Ladies Luncheon, Elise Lefkowitz, and her daughter, Charlie Lefkowitz Crowley, who surprised her mother with a special tribute at the Tenth Annual Great Ladies Event.
# NEW AND CONTINUING PROGRAMS

The programs listed in this section of the report were active within the ADDF’s portfolio as of December 31, 2020.

*Indicates ADDF support of different programs led by the same researcher.

## BIOMARKERS

Biomarkers are tools used to diagnose a disease and assess its progression and response to treatment. These researchers aim to develop more accurate biomarkers for clinical trials.

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leyla Anderson, MD, PhD, D(ABMLI)</td>
<td>NeuroVision Imaging, Inc.</td>
<td>$539,259.00</td>
</tr>
<tr>
<td>Rhoda Au, PhD</td>
<td>Trustees of Boston University</td>
<td>$1,937,857.00</td>
</tr>
<tr>
<td>Marta Barrachina, PhD, MBA</td>
<td>ADMit Therapeutics S.L.</td>
<td>$497,652.00</td>
</tr>
<tr>
<td>Kaj Blennow, MD, PhD</td>
<td>University of Gothenburg</td>
<td>$500,000.00</td>
</tr>
<tr>
<td>Yuval Dor, PhD</td>
<td>Hebrew University, Faculty of Medicine</td>
<td>$500,000.00</td>
</tr>
<tr>
<td>Chris Edgar, PhD</td>
<td>Cogstate Ltd</td>
<td>$1,360,000.00</td>
</tr>
<tr>
<td>Douglas Galasko, MD</td>
<td>University of California, San Diego</td>
<td>$375,000.00</td>
</tr>
<tr>
<td>Sam Gandy, MD, PhD</td>
<td>Icahn School of Medicine at Mount Sinai</td>
<td>$187,069.00</td>
</tr>
<tr>
<td>John Gerdes, PhD</td>
<td>RIO Pharmaceuticals, Inc.</td>
<td>$308,869.00</td>
</tr>
<tr>
<td>John Harrison</td>
<td>Neurotrack Technologies, Inc.</td>
<td>$792,990.00</td>
</tr>
<tr>
<td>Wesley Horton</td>
<td>Foundation for the National Institutes of Health, Inc.</td>
<td>$402,000.00</td>
</tr>
<tr>
<td>Laura Ibanez, PhD</td>
<td>Washington University in St. Louis</td>
<td>$281,370.00</td>
</tr>
<tr>
<td>Clifford Jack, MD</td>
<td>Mayo Clinic Rochester</td>
<td>$499,143.00</td>
</tr>
<tr>
<td>Name</td>
<td>Institution/Role</td>
<td>Amount</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Russell Lebovitz, MD, PhD</td>
<td>Ampriion Inc</td>
<td>$631,653.00</td>
</tr>
<tr>
<td>Cecilia Lee, MD, MS</td>
<td>University of Washington</td>
<td>$498,958.00</td>
</tr>
<tr>
<td>Chunlei Liu, PhD</td>
<td>Regents of the University of California at Berkeley</td>
<td>$300,000.00</td>
</tr>
<tr>
<td>Franc Llorens</td>
<td>CIBERNE-CNB-CSIC</td>
<td>$228,000.00</td>
</tr>
<tr>
<td>Val Lowe, MD</td>
<td>Mayo Clinic Rochester</td>
<td>$347,582.00</td>
</tr>
<tr>
<td>Tom MacGillivray, BSc, MSc, PhD</td>
<td>University of Edinburgh</td>
<td>$488,997.00</td>
</tr>
<tr>
<td>Saliha Moussaoui, PhD</td>
<td>Neurosciences, Master Phamcacochemistry,</td>
<td>$2,000,000.00</td>
</tr>
<tr>
<td></td>
<td>Certified International Team Leadership,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Certified Project Management, Amoneta Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Amber Murray, PhD</td>
<td>Biological Dynamics, Inc.</td>
<td>$1,836,770.00</td>
</tr>
<tr>
<td>Gerard Nuovo, MD</td>
<td>Gnome Diagnostics, LLC</td>
<td>$181,750.00</td>
</tr>
<tr>
<td>Rodney Pearlman, PhD</td>
<td>Bluefield Project to Cure FTD</td>
<td>$1,200,000.00</td>
</tr>
<tr>
<td>Gregory Penner, PhD</td>
<td>NeoNeuro</td>
<td>$363,000.00</td>
</tr>
<tr>
<td>Martin Pomper, MD, PhD</td>
<td>Precision Molecular Inc.</td>
<td>$561,111.00</td>
</tr>
<tr>
<td>Ramit Ravona-Springer, MD</td>
<td>Medical Research Development and Health Services Fund by the Sheba Medical Center</td>
<td>$249,810.00</td>
</tr>
<tr>
<td>Blaine Roberts, PhD</td>
<td>Florey Institute of Neuroscience and Mental Health</td>
<td>$149,518.00</td>
</tr>
<tr>
<td>Eliav Shaked, MSc</td>
<td>RetiSpec Inc.</td>
<td>$500,000.00</td>
</tr>
<tr>
<td>Keith St. Lawrence, PhD</td>
<td>Lawson Health Research Institute</td>
<td>$163,626.00</td>
</tr>
<tr>
<td></td>
<td>(Affiliated with University of Western Ontario)</td>
<td></td>
</tr>
<tr>
<td>Judith Steen, PhD</td>
<td>Boston Children’s Hospital</td>
<td>$572,678.00</td>
</tr>
<tr>
<td>Bruno Steintraus, PhD</td>
<td>Hummingbird Diagnostics GmbH</td>
<td>$714,812.34</td>
</tr>
<tr>
<td>Sidney Strickland, PhD</td>
<td>The Rockefeller University</td>
<td>$320,000.00</td>
</tr>
<tr>
<td>Peter Stys, MD</td>
<td>University of Calgary</td>
<td>$293,369.00</td>
</tr>
<tr>
<td>Kelly Umana</td>
<td>Foundation for the National Institutes of Health, Inc.</td>
<td>$75,000.00</td>
</tr>
<tr>
<td>Samuil Umansky, MD, PhD</td>
<td>DiamiR Biosciences</td>
<td>$492,000.00</td>
</tr>
<tr>
<td>Peter van Wijngaarden, MBBS, PhD, FRANZCO</td>
<td>Centre for Eye Research Australia</td>
<td>$420,321.00</td>
</tr>
<tr>
<td>Paul Worley, MD</td>
<td>Johns Hopkins University</td>
<td>$160,000.00</td>
</tr>
<tr>
<td>Guoliang Xing, PhD</td>
<td>The Chinese University of Hong Kong</td>
<td>$641,204.00</td>
</tr>
<tr>
<td>Kevin Yarasheski, PhD</td>
<td>C2N Diagnostics</td>
<td>$2,225,237.00</td>
</tr>
<tr>
<td>Henrik Zetterberg, MD, PhD</td>
<td>University of Gothenburg</td>
<td>$3,197,896.00</td>
</tr>
</tbody>
</table>
**GENETICS & EPIGENETICS**  
These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Phase</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miles Berger, MD, PhD</td>
<td>Duke University</td>
<td>Clinical 2</td>
<td>$1,631,197.00</td>
</tr>
<tr>
<td>Roger Bullock, PhD, BA, MA</td>
<td>Oryzon Genomics S.A.</td>
<td>Clinical 2</td>
<td>$1,500,000.00</td>
</tr>
<tr>
<td>Ronald Crystal, MD</td>
<td>LEXEO Therapeutics*</td>
<td>Clinical 2</td>
<td>$1,977,336.00</td>
</tr>
<tr>
<td>Kent Leslie</td>
<td>Amylyx Pharmaceuticals, Inc.</td>
<td>Clinical 2</td>
<td>$928,234.00</td>
</tr>
<tr>
<td>Hussein Yassine, MD</td>
<td>University of Southern California</td>
<td>Clinical 2</td>
<td>$1,500,000.00</td>
</tr>
</tbody>
</table>

**INFLAMMATION**  
These scientists are investigating drugs that protect against inflammation in the brain caused by disease and injury, which can accelerate or trigger Alzheimer’s.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Phase</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Hodgetts, PhD</td>
<td>Laboratory for Drug Discovery in Neurodegeneration (LDDN)</td>
<td></td>
<td>$600,000.00</td>
</tr>
<tr>
<td>Sharon Inouye, MD, MPH</td>
<td>Hebrew SeniorLife</td>
<td></td>
<td>$1,069,609.00</td>
</tr>
<tr>
<td>Masashi Kitazawa, PhD</td>
<td>University of California, Irvine</td>
<td></td>
<td>$328,000.00</td>
</tr>
<tr>
<td>Krista Lanctôt, PhD</td>
<td>Sunnybrook Research Institute</td>
<td></td>
<td>$1,396,867.00</td>
</tr>
<tr>
<td>John Olichney, MD</td>
<td>University of California at Davis</td>
<td></td>
<td>$1,034,991.00</td>
</tr>
<tr>
<td>Michael Parker, DPhil, FAA, FAHMS</td>
<td>St. Vincent’s Institute of Medical Research</td>
<td></td>
<td>$345,754.00</td>
</tr>
<tr>
<td>Erik Roberson, MD, PhD</td>
<td>University of Alabama at Birmingham</td>
<td></td>
<td>$660,000.00</td>
</tr>
<tr>
<td>Marwan Sabbagh, MD</td>
<td>Cleveland Clinic Lou Ruvo Center for Brain Health</td>
<td>Clinical 2</td>
<td>$1,396,475.00</td>
</tr>
<tr>
<td>Eric Siemens, MD</td>
<td>Vaccinex Inc.</td>
<td>Clinical 1</td>
<td>$2,992,766.00</td>
</tr>
<tr>
<td>Edward Spack, PhD</td>
<td>Therini Bio</td>
<td></td>
<td>$3,000,000.00</td>
</tr>
<tr>
<td>Meredith Upton</td>
<td>Foundation for the National Institutes of Health, Inc.</td>
<td></td>
<td>$100,000.00</td>
</tr>
<tr>
<td>Linda Van Eldik, PhD</td>
<td>University of Kentucky Research Foundation</td>
<td>Clinical 1</td>
<td>$1,434,160.00</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>Phase</td>
<td>Funding</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Manfred Windisch, PhD</td>
<td>Neurokine Therapeutics</td>
<td>Clinical Phase 1</td>
<td>$1,688,985.00</td>
</tr>
<tr>
<td>Dirk Beher, PhD</td>
<td>Asceneuron SA</td>
<td>Clinical Phase 1</td>
<td>$2,200,000.00</td>
</tr>
<tr>
<td>Travis Dunckley, PhD</td>
<td>Arizona State University Foundation</td>
<td></td>
<td>$224,753.00</td>
</tr>
<tr>
<td>Luana Fioriti, PhD</td>
<td>Plico Biotech Inc.</td>
<td></td>
<td>$148,000.00</td>
</tr>
<tr>
<td>Edward Huey, MD</td>
<td>Trustees of Columbia University in the City of New York</td>
<td>Clinical Phase 2</td>
<td>$532,335.00</td>
</tr>
<tr>
<td>Christopher Hulme, PhD</td>
<td>University of Arizona</td>
<td></td>
<td>$99,964.00</td>
</tr>
<tr>
<td>Janice Kranz, PhD</td>
<td>Eikonizo Therapeutics, Inc.</td>
<td>Clinical Phase 0</td>
<td>$1,001,051.00</td>
</tr>
<tr>
<td>Thomas Kukar, PhD</td>
<td>Emory University</td>
<td></td>
<td>$150,000.00</td>
</tr>
<tr>
<td>Raymond Turner, MD, PhD</td>
<td>Georgetown University</td>
<td>Clinical Phase 2</td>
<td>$2,104,000.00</td>
</tr>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPI</td>
<td>Imperial College London</td>
<td>Clinical Phase 2</td>
<td>$458,000.00</td>
</tr>
<tr>
<td>Gary Gibson, PhD</td>
<td>Winifred Masterson Burke Medical Research Institute</td>
<td>Clinical Phase 2</td>
<td>$250,000.00</td>
</tr>
<tr>
<td>Eugenia Trushina, PhD</td>
<td>Mayo Clinic Rochester</td>
<td></td>
<td>$600,000.00</td>
</tr>
<tr>
<td>Roberta Diaz Brinton, PhD</td>
<td>University of Arizona</td>
<td>Clinical Phase 2</td>
<td>$450,000.00</td>
</tr>
</tbody>
</table>

**MISFOLDED PROTEINS**

These scientists are pursuing approaches to prevent or clear the accumulation of misfolded proteins, which causes damage to brain cells.

**MITOCHONDRIA & METABOLIC FUNCTION**

As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

**NEUROPROTECTION**

As Alzheimer's progresses, neurons (or nerve cells) lose their connections and begin to die, causing the loss of memory and other cognitive functions. These scientists are exploring “neuroprotective” treatment strategies to shield neurons from damage and death.
Susan Catalano, PhD  
Cognition Therapeutics, Inc.  
Clinical Phase 2  
$2,000,000.00

Thomas Franke, MD, PhD  
Icahn School of Medicine at Mount Sinai  
$233,505.11

Dimitrios Kapogiannis, MD  
National Institute on Aging  
$336,432.00

Leen Kawas, PhD  
Athira Pharma Inc.  
Clinical Phase 1  
$1,397,630.00

Frank Longo, MD, PhD  
PharmatrophiX  
Clinical Phase 2  
$500,000.00

William Ray, PhD  
The Neurodegeneration Consortium, MD Anderson  
$538,620.00

Emiliano Santarnecchi, PhD  
Harvard Medical School/BIDMC  
Clinical Phase 2  
$1,959,841.00

Grace Stutzmann, PhD  
NeuroLucent, Inc.  
RFUMS/Chicago Medical School*  
$338,985.00

Ronald van der Geest, PhD  
Treeway B.V.  
Clinical Phase 2  
$2,994,122.57

John “Kent” Werner, MD, PhD  
Cogentis Therapeutics  
$188,193.00

Yan Zhang, PhD  
The University of Texas at Austin  
$350,000.00

Jeffrey Cummings, MD  
Cleveland Clinic Lou Ruvo Center for Brain Health  
Clinical Phase 2  
$1,000,000.00

Cleveland Clinic Lou Ruvo Center for Brain Health*  
$24,300.92

Michela Gallagher, PhD  
AgeneBio Inc.  
Clinical Phase 3  
$150,000.00

Wesley Horton  
Foundation for the National Institutes of Health, Inc.  
$300,000.00

Giacomo Koch, MD, PhD  
Santa Lucia Foundation  
Clinical Phase 2  
$602,800.00

Santa Lucia Foundation*  
$250,000.00

Chien-liang Lin, PhD  
Ohio State University  
$795,235.00

Alexandros Makriyannis, PhD  
Northeastern University  
$250,000.00

Paul Newhouse, MD  
Vanderbilt University  
Clinical Phase 2  
$1,271,174.00

Vanderbilt University*  
$539,798.53

Ana Pereira, MD  
Icahn School of Medicine at Mount Sinai  
Clinical Phase 2  
$106,000.00

SYNAPTIC ACTIVITY & NEUROTRANSMITTERS
Neurotransmitters carry signals across synapses, which are connections between neurons. These processes are critical for memory and cognition.
Healthy blood flow is essential for providing neurons with sufficient oxygen and vital nutrients. These researchers are targeting vascular damage to improve brain function.

VASCULAR

Sharon Rosenzweig-Lipson, PhD
AgeneBio Inc. $499,704.00

Jerri Rook, PhD
Vanderbilt University $150,000.00

Sandra Black, MD, FRCP(C)
Sunnybrook Research Institute, University of Toronto
Clinical Phase 2 $450,000.00

Atticus Hainsworth, PhD
St. George’s University of London
Clinical Phase 2 $464,992.00

Ihab Hajjar, MD, MS
Emory University
Clinical Phase 2 $973,777.00

OTHER

Dieter Edbauer, MD
German Center for Neurodeenerative Diseases $300,000.00

Riccardo Miotto, PhD
Icahn School of Medicine at Mount Sinai $100,000.00

Miranda Orr, PhD
Wake Forest University Health Sciences
Clinical Phase 2 $3,000,000.00

Irina Pikuleva, PhD
Case Western Reserve University
Clinical Phase 2 $197,475.00

Hiroaki Sato, MD, PhD
McGill University
Clinical Phase 2 $782,461.00

Phillip Tully, PhD, MPsych, BHSc
University of Adelaide $99,363.00

Bruno Vellas, MD
Toulouse Centre of Excellence in Neurodegeneration, University Hospital Toulouse
Clinical Phase 2 $300,000.00

George Vradenburg
UsAgainstAlzheimer’s Network $1,000,000.00

Kristine Yaffe, MD
The Regents of the University of California, San Francisco $100,000.00

$88,110,456.47
TOTAL SUPPORT FOR NEW AND CONTINUING PROGRAMS
OUR SUPPORTERS

We are deeply grateful to all those who supported our work in 2020. Your generosity gives us hope for a future without Alzheimer’s disease.

$1,000,000 AND ABOVE
Anonymous (2)
Association for Frontotemporal Degeneration
Jeffrey Bezos
Dagmar Dolby Fund
Foundation for a Better World
Gates Ventures
Judy and Leonard A. Lauder
MacKenzie Scott

$500,000–$999,999
Charles and Helen Schwab Foundation
Edward Goodnow
Jo Carole and Ronald S. Lauder

$250,000–$499,999
Anonymous
Lattner Family Foundation
The Lauder Foundation
Melvin R. Goodes Family Foundation

$100,000–$249,999
Roslyn Goldstein
Nancy and Melvin R. Goodes
Frances and Nathan Kirsh
Laurence C. Leeds, Jr.
Susan and Thomas Lowder
The Ludwig Family Foundation
Michael and Catherine Podell
Ray and Kay Eckstein Charitable Trust
Samuel I. Newhouse Foundation, Inc.
Lizbeth Furman Sandler and Randal Sandler
The Joan G. Toepfer Charitable Trust
Tuchman Family Foundation
Carolyn and Malcolm Wiener

$25,000–$49,999
Anonymous
A.G. Foundation
Hope and Marc Altheim
Beacon Investment Advisory Services
Bloomberg Philanthropies
Carol Seabrook Boulanger
Joan and Ed Doherty
Cynthia Breen and Laurie Dowley
Eli Lilly and Company
Bonnie Englebardt Lautenberg
The Estée Lauder Companies Inc.
Ellie Lilly and Company
Donna Englebardt Lautenberg
Katherine Kamen

$10,000–$24,999
Anonymous (3)
Albert B. Glickman Family Foundation
Amy Baier
Shelley and Robert Banks
Ruth Baum
Judy and Howard Bernick
Daniel S. Bernstein
Michele Beyer
Leslie Bhutani
Lynn and Wolf Blitzer
Faith Bobrow
Charles Bronfman
Henry Buhl
James Buller
Ron Burkle
Linda and Arthur Carter
Kristin and John Cecchi
Clifford Chance US LLP
Neil Cohen
Ryna & Melvin Cohen Family Foundation Inc.
Colliers International
Gina and Kurt Conti
Crown Equipment Corporation
James and Janet Dicke
Annette and Mitchell Eichen
Ernst & Young LLP
Mary C. Farrell
Jerald D. Fessenden
Foerster Bernstein Foundation
Marilyn and Sam Fox
Richard I. Furman
Paul and Elizabeth Greenbaum
Philip M. Gross
Audrey and Martin Gruss
Dena Henry
Lawrence Herbert
Ronnie F. Heyman
Howard Gilman Foundation
Jane Hertzmark Hudis and Clifford Hudis
Hues for You, LLC
Jones Lang LaSalle America Inc.
JP Morgan Chase
Katherine Kamien
Barbara and Ron Kaufman

OUR SUPPORTERS

We are deeply grateful to all those who supported our work in 2020. Your generosity gives us hope for a future without Alzheimer’s disease.
Thank you to the ADDF... for your ongoing support of drug discovery. The bench-to-bedside journey is complicated and challenging, but new doors are opening for research and science as philanthropic groups like the ADDF become more involved in the process.

Jerri M. Rook, PhD
Recipient, Melvin R. Goodes Prize

GT Flagler Limited Partnership, LLC
G-III Leather Fashions, Inc.
Beth and James Glassman
Ronald Gold
Alison Grann
Allison and Robert Grigg
HCMC Inc.
Heart of Neiman Marcus Foundation Fund
Thomas Hilfiger
Ann W. Jackson
Amy and Scott Jaffee

Allison and Howard Lutnick
The Marc Haas Foundation
Morris Mark
David H. McCormick
David Moscow
Linda and Sidney Moskowitz
Night Owl Capital Management LLC
Melanie and Lawrence Nussdorf
Pamela and Edward Panter
Charles and Donna Reilly
David Reis
Denise Rich
Paula Robinson
Ronald Rosner
Janet C. Ross
Sacks & Sacks LLP
Roger W. Sant
Edith and Gerald Schaeffer
June and Paul Schorr
Shana Alexander Charitable Foundation
Stuart Sherrill
Barbara Diamonstein-Spielvogel and Carl Spielvogel
The Whittier Trust Company
Nikola Theo
UBS Private Wealth Management
Ann and Thomas Unterberg
Sara and John Walsh

Ross P. Waller
Tamara Watkins
Sandra E. Wegman
Janice Worth
Alison and Boniface Zaino

$5,000–$9,999
William Acquavella
Yousef Al Otaiba
Bettina Anderson
Roger Anderson
Shari and Jeff Aronson

Joyce Cowin
CustomInk LLC
Daniell Family Foundation
Ellen Davin
John D. Demsey
Cindy and Glen Edelman
Susan Efron
Peter Engel
First Republic Bank
Julie Garcia
George Gardner Monks Foundation
Clark Enterprises, Inc.

Kiera and Christopher Johnson
Christopher and Vicki Kellogg
Kelsey Family Foundation
Eleanora R. Kennedy
Al W. King
George Klett
Diana Kogan and Israel Kogan
Elyse Kroll
Dana and Michael Landow
Linda and Steven Levy
Sharon Handler-Loeb and John Loeb
LoveShackFancy
LEADERSHIP

BOARD OF GOVERNORS

The Board of Governors is the principal board of the Corporation with all legal power and authority to manage, oversee, and make decisions regarding the ADDF’s programs and activities. Board members include leaders from government, industry, and the research community, who serve as ambassadors for the ADDF and provide strategic oversight and counsel.

All members as of December 31, 2020.

ADDF HONORARY CHAIR (RETIRED)
Justice Sandra Day O’Connor
Associate Justice, US Supreme Court

CO-CHAIRS
Leonard A. Lauder
Chairman Emeritus, The Estée Lauder Companies Inc.
Ronald S. Lauder
Chairman, Clinique Laboratories, LLC

CO-VICE CHAIR AND SECRETARY
Randal Sandler
Director of Client Services and Marketing, Bridgewater Associates

EX OFFICIO
Howard Fillit, MD
Founding Executive Director and Chief Science Officer

CO-VICE CHAIR AND TREASURER
Thomas F. McWilliams
Private Investor

GOVERNORS
Robert Belfer
Chairman, Belfer Management
Roberta Diaz Brinton, PhD
Inaugural Director of the Center for Innovation in Brain Science at the University of Arizona, Professor of Pharmacology and Neurology in the College of Medicine, Tucson
Nancy Corzine
President and CEO, Nancy Corzine Inc.
Lanny Edelsohn, MD
Director, Christiana Care Health Systems, Inc.
Bonnie Pfeifer Evans
Senior Sales Associate, Corcoran Group Real Estate; Co-Trustee, The Charles Evans Foundation

Melvin R. Goodes*
Former Chairman and CEO, Warner-Lambert
Nancy Goodes
Former Executive, Nazareth-Century Mills; Secretary, Melvin R. Goodes Family Foundation, Inc.
Gary M. Lauder
Managing Director, Lauder Partners LLC
Laurence C. Leeds, Jr.
Chairman, Buckingham Capital Management, Inc.
Richard C. Mohs, PhD
Global Alzheimer’s Platform Foundation
Beatriz Illescas Putzeys-Claugus
Educator, Sworn Translator, Diplomat, Philanthropist, Founder of The Foundation for a Better World
Sharon T. Sager, CIMA
Managing Director and Private Wealth Advisor, UBS Private Wealth Management
Alice Shure
Founder and Producer, AMICI Productions LLC; Co-Trustee, The Charles Evans Foundation
Sally Susman*
Executive Vice President, Policy, External Affairs and Communications, Pfizer Inc.
David R. Weinreb
Chief Executive Officer, Weinreb Ventures

*Denotes Honorary Members
The Board of Overseers is an advisory body committed to providing counsel and support to the ADDF Board of Governors and staff. Overseers lend their expertise to advance the ADDF’s mission to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease. Overseers are appointed by and serve at the pleasure of the Board of Governors.

*All members as of December 31, 2020.*

**CHAIR**
Sharon T. Sager, CIMA
Managing Director and Private Wealth Advisor, UBS Private Wealth Management

**OVERSEERS**
Carol Seabrook Boulanger
Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP

Charles Cangro
Principal, Personal Financial Services, Ernst & Young, LLC (Retired)

Mitchell D. Eichen, J.D., LL.M.
Founder and Chief Executive Officer, Acertus Capital Management
Founder and Chief Executive Officer, The MDE Group

Stephanie Ginsberg
Volunteer, Philanthropist; Founder, BCRF Pink Promises Benefit

Allan M. Green, MD, PhD, JD
Allan M. Green Esq., LLC

Christopher Johnson
President, Rackson Companies

Mitchell Kanef
Chairman and CEO, Arkay Packaging

Bonnie Englebardt Lautenberg
Photographer and Writer, Bonnie Lautenberg Designs

Elise Gelman Lefkowitz
Philanthropist

Philip Lovett
Founding Partner, Millennium Partners

Julie Medler
Managing Director, Golden Seeds

Justin Meltzer
Real Estate Operations, DLA Piper LLP

Pamela J. Newman, PhD
President and Chief Executive Officer, PJN Strategies

Phebe Farrow Port
Senior Vice President, Global Management Strategies and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies Inc.

Gregory A. Rosica
Partner, Tax, Ernst & Young, LLC

Tom Scanlan
Consultant, Spencer Stuart

John H. Scully, CIMA
Senior Managing Director, Head of Private Wealth Advisory, Nuveen Investments

Stephen Toma
Managing Director, VJMS, LLC

Wendy L. Wilshin
Founder and Principal, WLW Designs
2020 ANNUAL REPORT

FINANCIAL OVERVIEW

*Full audited 2020 financials available by request

STATEMENT OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$31,201,758</td>
<td>9,749,518</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>43,655,426</td>
<td>76,370,497</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>22,155,205</td>
<td>11,255,768</td>
</tr>
<tr>
<td>Other assets</td>
<td>163,175</td>
<td>5,940</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>97,175,564</td>
<td>97,381,723</td>
</tr>
</tbody>
</table>

LIABILITIES & NET ASSETS

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable &amp; accrued liabilities</td>
<td>215,799</td>
<td>82,515</td>
</tr>
<tr>
<td>Grants payable</td>
<td>46,629,104</td>
<td>47,599,968</td>
</tr>
<tr>
<td>Due to Institute for the Study of Aging, Inc.</td>
<td>5,362</td>
<td>402,676</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>108,331</td>
<td>16,000</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>46,958,596</td>
<td>48,101,159</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>22,108,235</td>
<td>22,199,906</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>28,108,733</td>
<td>27,060,658</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>50,216,968</td>
<td>49,280,564</td>
</tr>
</tbody>
</table>

| Total liabilities & net assets        | $97,175,564 | 97,381,723  |

STATEMENT OF ACTIVITIES

CHANGE IN NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2020 Without Donor Restrictions</th>
<th>2020 With Donor Restrictions</th>
<th>2019 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support &amp; Revenues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions &amp; grants</td>
<td>$3,944,505</td>
<td>15,717,622</td>
<td>19,662,127</td>
</tr>
<tr>
<td>Contributions of in-kind services from the Institute for the Study of Aging, Inc.</td>
<td>3,363,452</td>
<td>—</td>
<td>3,363,452</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>1,887,157</td>
<td>—</td>
<td>1,887,157</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>16,756,656</td>
<td>(16,756,656)</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total Support &amp; Revenues</strong></td>
<td>31,727,032</td>
<td>(1,048,075)</td>
<td>30,678,957</td>
</tr>
</tbody>
</table>

| Expenses                  |                                 |                              |            |
| Program services:         |                                 |                              |            |
| Grants                    | 30,869,812                      | —                            | 30,869,812 |
| Unexecuted prior year grants | (6,068,743)                  | —                            | (6,068,743) |
| Other                     | 4,257,402                       | —                            | 4,257,402  |
| **Total Program Services** | 29,058,471                    | —                            | 29,058,471 |

| Support services:         |                                 |                              |            |
| Fundraising               | 1,421,435                       | —                            | 1,421,435  |
| Management & general      | 1,135,455                       | —                            | 1,135,455  |
| **Total Supporting Services** | 2,556,890                   | —                            | 2,556,890  |

| **Total Expenses**        | 31,615,361                      | —                            | 31,615,361 |

| Change in net assets      | 111,671                        | (1,048,075)                  | (936,404)  |
| Net assets, end of year   | $22,219,906                    | 27,060,658                   | 49,280,564 |

| **Total liabilities & net assets** | $97,175,564 | 97,381,723 |
100% OF YOUR DONATION FUNDS SCIENCE

All fundraising and management expenses are underwritten by our founders, so your entire donation funds innovative science.

*We're proud to hold GuideStar's Platinum charity rating.*
Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only philanthropy solely focused on accelerating the development of drugs to prevent, treat, and cure Alzheimer’s disease. Its venture philanthropy approach and scientific expertise allows the ADDF to support the most promising ideas around the world. And 100% of your donation funds innovative science.

To learn more, visit AlzDiscovery.org